Investors’ data
Latest news
- February 23, 2010
Thallion Announces 2009 Year End Results
- February 16, 2010
Thallion Pharmaceuticals and LFB biotechnologies Sign Definitive Agreement to Develop and Commercialize Treatment for E. Coli (STEC) Infection
- January 11, 2010
Thallion Announces Changes to Executive Management Structure and Board of Directors
Documentation
Investors Overview
Corporate Office
7150 Alexander-Fleming
Montreal, Quebec
H4S 2C8
Phone: 514-940-3600
Fax: 514-940-3622